Fast Track, Breakthrough, and Accelerated Approvals: Impact on U.S. Clinical Trials
Fast Track, Breakthrough, and Accelerated Approvals: Impact on U.S. Clinical Trials Understanding FDA Expedited Programs and Their Impact on U.S. Clinical Trials Introduction The Food and Drug Administration (FDA) has established expedited approval pathways to accelerate the development and review of drugs addressing serious or life-threatening conditions. These include Fast Track designation, Breakthrough Therapy designation,…
Read More “Fast Track, Breakthrough, and Accelerated Approvals: Impact on U.S. Clinical Trials” »